Phase 3Recruiting
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO-GREEN)
RAINBO: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features, TransPORTEC Platform Trials - MMRd-GREEN.
- Sponsor
- Leiden University Medical Center (Academic or other)
- Enrolment
- 316 planned
- Conditions
- Endometrial Cancer
- Interventions
- Pelvic external beam radiotherapy; Chemotherapy; Durvalumab; Vaginal brachytherapy
- Ages
- adults, older adults
- Registry
- NCT05255653
Full record on ClinicalTrials.gov
From the registry
RAINBO MMRd-GREEN is an international, multicenter, phase III randomised trial wherein adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab for one year is compared to adjuvant pelvic external beam radiotherapy with or without chemotherapy.
Primary outcomes
- Recurrence-free survival
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started